Skip to main content
Industry News
Amgen's ALL therapy gets NICE recommendation

Amgen's Blincyto, or blinatumomab, received a recommendation for approval from the National Institute for Health and Care Excellence as a treatment for patients with acute lymphoblastic leukemia who are in first complete remission with minimal residual disease activity of 0.1% or more. The cost regulator considered the therapy cost-effective.

Full Story: